MML Investors Services LLC Has $660,000 Stock Holdings in LeMaitre Vascular, Inc. (NASDAQ:LMAT)

MML Investors Services LLC raised its holdings in LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 2.8% in the 3rd quarter, HoldingsChannel reports. The fund owned 7,107 shares of the medical instruments supplier’s stock after acquiring an additional 191 shares during the period. MML Investors Services LLC’s holdings in LeMaitre Vascular were worth $660,000 at the end of the most recent quarter.

Other large investors have also recently modified their holdings of the company. XTX Topco Ltd acquired a new stake in LeMaitre Vascular in the third quarter valued at $344,000. DF Dent & Co. Inc. increased its stake in shares of LeMaitre Vascular by 26.2% in the third quarter. DF Dent & Co. Inc. now owns 258,767 shares of the medical instruments supplier’s stock valued at $24,037,000 after buying an additional 53,797 shares during the period. State Street Corp raised its position in shares of LeMaitre Vascular by 3.6% during the third quarter. State Street Corp now owns 822,085 shares of the medical instruments supplier’s stock worth $76,363,000 after acquiring an additional 28,525 shares during the last quarter. Stifel Financial Corp boosted its holdings in LeMaitre Vascular by 10.8% in the third quarter. Stifel Financial Corp now owns 72,194 shares of the medical instruments supplier’s stock valued at $6,706,000 after acquiring an additional 7,060 shares during the last quarter. Finally, Quadrature Capital Ltd acquired a new stake in LeMaitre Vascular during the 3rd quarter valued at approximately $281,000. Institutional investors own 84.64% of the company’s stock.

Analysts Set New Price Targets

LMAT has been the topic of a number of recent analyst reports. StockNews.com downgraded shares of LeMaitre Vascular from a “buy” rating to a “hold” rating in a research report on Friday, December 13th. Oppenheimer reiterated an “outperform” rating and set a $93.00 price target (up from $90.00) on shares of LeMaitre Vascular in a report on Friday, November 1st. Cantor Fitzgerald assumed coverage on LeMaitre Vascular in a research note on Tuesday, October 15th. They issued a “neutral” rating and a $96.00 price objective on the stock. Finally, Barrington Research raised their target price on LeMaitre Vascular from $92.00 to $93.00 and gave the stock an “outperform” rating in a research note on Friday, November 1st. Three research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, LeMaitre Vascular presently has a consensus rating of “Moderate Buy” and an average price target of $94.57.

Insider Activity

In other news, Director Bridget A. Ross sold 3,750 shares of the firm’s stock in a transaction that occurred on Friday, November 15th. The stock was sold at an average price of $101.47, for a total value of $380,512.50. Following the transaction, the director now owns 2,278 shares in the company, valued at $231,148.66. This trade represents a 62.21 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 10.79% of the company’s stock.

LeMaitre Vascular Price Performance

Shares of LMAT opened at $92.12 on Friday. The stock has a 50-day moving average of $97.75 and a 200-day moving average of $90.00. LeMaitre Vascular, Inc. has a one year low of $52.88 and a one year high of $109.58. The company has a market cap of $2.07 billion, a PE ratio of 50.34, a P/E/G ratio of 2.47 and a beta of 0.93.

LeMaitre Vascular (NASDAQ:LMAT) last released its quarterly earnings data on Thursday, October 31st. The medical instruments supplier reported $0.49 EPS for the quarter, beating the consensus estimate of $0.44 by $0.05. LeMaitre Vascular had a return on equity of 13.15% and a net margin of 19.40%. The firm had revenue of $54.82 million during the quarter, compared to the consensus estimate of $53.50 million. During the same quarter in the previous year, the company posted $0.33 earnings per share. The company’s quarterly revenue was up 15.6% on a year-over-year basis. Analysts expect that LeMaitre Vascular, Inc. will post 1.94 EPS for the current fiscal year.

LeMaitre Vascular Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, December 5th. Shareholders of record on Thursday, November 21st were paid a $0.16 dividend. This represents a $0.64 dividend on an annualized basis and a dividend yield of 0.69%. The ex-dividend date was Thursday, November 21st. LeMaitre Vascular’s dividend payout ratio (DPR) is 34.97%.

LeMaitre Vascular Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.